Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 27, 2025
Daily News
November 27, 2025
- New Govt Casts Pharma as Core Industry, Minister Says at Public-Private Confab
November 27, 2025
- MHLW Floats Prefectural Bodies for Regional Formularies, LLP Copay Hike Gains Traction: LDP-Ishin Talks
November 27, 2025
- Otsuka’s Sibeprenlimab Earns FDA’s Accelerated Nod for IgAN
November 27, 2025
- MHLW Orders Label Revisions for Anticoagulants, Ondexxya, Tracleer, and More
November 27, 2025
- Japan PIII Trial Begins for Kagoshima University Spinout’s Oncolytic Virus
November 27, 2025
- Lawmakers Hold Cross-Party Study Session on Social Security
November 27, 2025
- Mochida, Ayumi Curb Shipments of Humira Biosimilar 40 mg amid Surging Orders
November 27, 2025
- Toray Out-Licenses Peripheral Neuropathy Drug to Sanodyne
November 27, 2025
- US Unveils Up to 85% Price Cuts for IRA Round-2; Astellas’ Xtandi on the List
November 27, 2025
- Renalys’ IgAN Drug Nets Positive PIII Data, 2026 Japan Filing on Track
November 27, 2025
- Rolling Submission for Leqembi SC Starting Dose Completed in US
November 27, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…